Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Cohance Lifesciences Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 369.36 | 347.55 | 231.05 | 219.82 | 252.93 | 488.08 | 603.77 | 676.23 | 840.42 | 549.31 | 555.57 | 544.55 | 619.12 |
| Expenses + | 197.50 | 180.59 | 133.09 | 153.74 | 179.58 | 362.98 | 398.40 | 438.86 | 611.20 | 437.30 | 434.62 | 449.20 | 520.44 |
| Operating Profit | 171.86 | 166.96 | 97.96 | 66.08 | 73.35 | 125.10 | 205.37 | 237.37 | 229.22 | 112.01 | 120.95 | 95.35 | 98.68 |
| OPM % | 46.53% | 48.04% | 42.40% | 30.06% | 29.00% | 25.63% | 34.01% | 35.10% | 27.27% | 20.39% | 21.77% | 17.51% | 15.94% |
| Other Income + | 11.40 | 10.67 | 19.84 | 14.34 | 17.05 | 19.41 | 16.19 | 21.56 | -3.73 | 6.07 | 15.60 | 1.30 | -18.35 |
| Interest | 5.03 | 1.15 | 0.50 | 2.16 | 2.30 | 10.20 | 9.61 | 10.80 | 10.45 | 10.18 | 8.76 | 9.11 | 9.19 |
| Depreciation | 12.02 | 12.54 | 11.89 | 12.79 | 17.25 | 31.28 | 37.79 | 43.56 | 54.17 | 45.14 | 44.02 | 46.94 | 51.23 |
| Profit before tax | 166.21 | 163.94 | 105.41 | 65.47 | 70.85 | 103.03 | 174.16 | 204.57 | 160.87 | 62.76 | 83.77 | 40.60 | 19.91 |
| Tax % | 25.41% | 26.44% | 24.51% | 28.59% | 24.67% | 26.85% | 20.62% | 24.97% | 27.18% | 26.07% | 20.75% | 28.52% | 58.26% |
| Net Profit + | 123.97 | 120.59 | 79.56 | 46.75 | 53.37 | 75.37 | 138.24 | 153.48 | 117.15 | 46.40 | 66.39 | 29.02 | 8.31 |
| EPS in Rs | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 |
Financials of Cohance Lifesciences Ltd
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 |
| Expenses + | 206 | 449 | 567 | 738 | 766 | 645 | 822 | 1,842 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 375 | 427 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 19% |
| Other Income + | 1 | 66 | 68 | 133 | 46 | 62 | 58 | 5 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 12 | 37 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 77 | 187 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 344 | 207 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 23% | 27% |
| Net Profit + | 109 | 317 | 362 | 454 | 411 | 300 | 265 | 150 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 4.68 | |
| Dividend Payout % | 0% | 20% | 14% | 28% | 37% | 0% | 0% | 0% |
Financials of Cohance Lifesciences Ltd
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.00 | 13 | 25 | 25 | 25 | 25 | 25 | 38 |
| Reserves | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 1,671 | 3,873 |
| Borrowings + | 83 | 186 | 143 | 97 | 70 | 65 | 279 | 400 |
| Other Liabilities + | 123 | 142 | 151 | 205 | 160 | 138 | 1,056 | 1,418 |
| Total Liabilities | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,730 |
| Fixed Assets + | 271 | 357 | 441 | 534 | 663 | 670 | 1,713 | 3,373 |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 | 256 | 173 |
| Investments | 7 | 338 | 542 | 598 | 536 | 904 | 337 | 529 |
| Other Assets + | 394 | 376 | 395 | 667 | 601 | 501 | 725 | 1,655 |
| Total Assets | 783 | 1,173 | 1,474 | 1,830 | 1,966 | 2,254 | 3,031 | 5,730 |
Financials of Cohance Lifesciences Ltd
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 50 | 407 | 383 | 330 | 457 | 358 | 288 | 368 |
| Cash from Investing Activity + | -65 | -413 | -311 | -136 | -195 | -362 | -253 | -255 |
| Cash from Financing Activity + | 26 | 7 | -76 | -156 | -242 | -14 | 3 | -165 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | 38 | -51 |
| Free Cash Flow | -6 | 304 | 272 | 255 | 171 | 307 | 132 | 169 |
| CFO/OP | 49% | 128% | 111% | 88% | 105% | 115% | 99% | 102% |
Financials of Cohance Lifesciences Ltd
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 46 | 87 | 110 |
| Inventory Days | 556 | 278 | 243 | 259 | 279 | 268 | 199 | 310 |
| Days Payable | 190 | 113 | 100 | 97 | 63 | 49 | 96 | 157 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 247 | 265 | 190 | 263 |
| Working Capital Days | 205 | 64 | 56 | 108 | 99 | 115 | 74 | 175 |
| ROCE % | 50% | 40% | 41% | 32% | 19% | 15% | 8% |